{"id":10798,"date":"2022-06-08T10:54:15","date_gmt":"2022-06-08T01:54:15","guid":{"rendered":"https:\/\/www.asamura.jp\/en\/?p=10798"},"modified":"2023-03-15T22:05:39","modified_gmt":"2023-03-15T13:05:39","slug":"wipo-submission-of-sequence-listings-in-accordance-with-the-provisions-of-wipo-standard-st-26","status":"publish","type":"post","link":"https:\/\/www.asamura.jp\/en1\/2022\/06\/08\/wipo-submission-of-sequence-listings-in-accordance-with-the-provisions-of-wipo-standard-st-26\/","title":{"rendered":"WIPO: Submission of Sequence Listings in accordance with the provisions of WIPO Standard ST.26"},"content":{"rendered":"\r\n

Jun 8, 2022<\/span><\/em><\/span><\/p>\r\n

\r\n

WIPO: Submission of Sequence Listings in accordance with the provisions of WIPO Standard ST.26<\/strong><\/span><\/em><\/h3>\r\n
\r\n

\u00a0<\/p>\r\n


\r\n
\r\n<\/span><\/p>\r\n

On July 1, 2022, the amendments to the PCT Regulations and the PCT Administrative Rules will enter into force. As a result, as of July 1, 2022, international and Japanese domestic applications* containing nucleotide or amino acid sequences will be required to submit sequence listings in accordance with the World Intellectual Property Organization (WIPO) standard ST.26.<\/span><\/p>\r\n

Not only the Japan Patent Office (JPO), but also the United States Patent and Trademark Office (USPTO), the European Patent Office (EPO), etc. will require submission of sequence listings for patent applications containing nucleotide or amino acid sequences in accordance with the provisions of WIPO standard ST.26 as of July 1, 2022. Applications filed before July 1, 2022 do not need to comply with WIPO standard ST.26.<\/span><\/p>\r\n

 <\/p>\r\n

The main differences between WIPO standard ST.26 and the previous regulation (standard ST.25) are as follows:<\/span><\/p>\r\n